Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2013, Article ID 196878, 3 pages
Case Report

Quasi-Complete Response of Classic Kaposi’s Sarcoma Treated with Weekly Paclitaxel

1Medical Oncology, Hassan II University Hospital, P.O. Box 8743, Fès, Morocco
2Service of Dermatology, Hassan II University Hospital, Fès, Morocco

Received 13 November 2012; Accepted 30 December 2012

Academic Editors: L. J. Layfield, F. A. Mauri, and J. I. Mayordomo

Copyright © 2013 Zineb Benbrahim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Classic Kaposi’s sarcoma (CKS) is a subtype that traditionally occurs in elderly HIV-negative males of Mediterranean origin. Patients with CKS characteristically present with skin lesions in the distal extremities. Involvement of the viscera is uncommon but may occur in the late stages of the disease. Patients with extensive KS can be treated with systemic chemotherapy. A number of drugs approved for treatment of AIDS-associated KS, especially Paclitaxel, have activity against CKS after failure of prior therapy. We report a patient treated with weekly Paclitaxel, as initial chemotherapy, for CKS presenting with multiple visceral involvement and having a contraindication for Bleomycin. The patient had quasi-complete response after three months of chemotherapy suggesting that weekly Paclitaxel might be effective as a first-line therapy for classical type KS with visceral involvement.